SHR2554 + adalimumab

**SHR2554 + adalimumab** is an investigational combination therapy comprised of the small molecule enhancer of zeste homolog 2 (EZH2) inhibitor SHR2554 and adalimumab, a fully human monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α). SHR2554 is an oral EZH2 inhibitor developed for oncologic indications, showing anti-tumor activity through inhibition of methyltransferase activity, cell cycle arrest, and induction of cancer cell apoptosis. Adalimumab is FDA-approved for various autoimmune diseases and works by inhibiting TNF-α to modulate inflammation. The combination is under investigation for antitumor effects, specifically in advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, likely aiming to target both tumor cell epigenetics and the tumor-promoting inflammatory microenvironment[1][2][3][4].

Brand names

Humira

Other names

adalimumab